Surbhi Sidana, MD

Surbhi Sidana, MD, is an associate professor of medicine and associate director for Clinical Research in the Bone Marrow Transplantation and Cell Therapy Division at Stanford University in California.

Articles

Dr Sidana on the FDA Approval of Belantamab Mafodotin Plus Vd in R/R Myeloma

October 31st 2025

Surbhi Sidana, MD, discusses belantamab mafodotin-blmf with bortezomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma.

Dr Sidana on the Efficacy of Second-Line Cilta-Cel in Relapsed/Refractory Myeloma

August 21st 2025

Surbhi Sidana, MD, discusses the PFS and OS benefit of second-line cilta-cel in patients with relapsed/refractory multiple myeloma.

Exciting Future Horizons for CAR T in MM and Take-Home Messages

April 28th 2025

Experts share their closing thoughts and key take-home messages from the discussion, summarizing important insights and takeaways for enhancing patient care and treatment strategies.

Clinical Perspectives: Importance of Vaccinations and Infection Prevention Post CAR T, and Monitoring Strategies for Other Potential Late CAR T–Related Toxicities in R/R MM

April 28th 2025

Experts discuss strategies for managing and mitigating early vs late chimeric antigen receptor (CAR) T-cell therapy–related toxicities, offering advice to practitioners, and share additional clinical pearls on improving the overall CAR T process in academic and community settings.

Collaborative Approach in Managing Post CAR T Care Between Academic and Community Physicians in R/R MM

April 21st 2025

Experts discuss how they manage chimeric antigen receptor (CAR) T-cell therapy follow-up care, highlighting the coordination between academic and community settings to ensure comprehensive monitoring and support for patients.

Overcoming Barriers to CAR T Referral in R/R MM

April 21st 2025

Experts discuss the challenges and barriers to early referral for chimeric antigen receptor (CAR) T-cell therapy, including logistical, financial, and patient-related factors that may impact timely access to treatment.

Explaining CAR T: Key Points for Patient Counseling

April 14th 2025

Experts discuss what they share with patients when counseling or introducing chimeric antigen receptor (CAR) T-cell therapy, focusing on the treatment process, potential benefits, risks, and expectations.

Bridging to CAR T in R/R MM: Best Practices

April 14th 2025

Experts discuss their optimal strategy for bridging therapy when preparing patients to receive chimeric antigen receptor (CAR) T-cell therapy. They focus on selecting therapies that maintain disease control while awaiting CAR T infusion.

Strategic Timing for CAR T in R/R MM: The Importance of Early Referral

April 7th 2025

Experts discuss when physicians should consider referring patients to chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (R/R MM). They emphasize the importance of early referral and access to CAR T in earlier lines of therapy while commenting on the similarities and differences in referral timing, particularly for patients treated in the community.

Cilta-cel vs. Ide-cel: Key Data Updates and Clinical Decision-Making in R/R MM

April 7th 2025

Experts discuss how they decide between utilizing cilta-cel vs ide-cel in multiple myeloma, considering factors like disease characteristics, patient factors, and product differences, while reviewing the final progression-free survival (PFS) analysis from the KarMMA-3 study with ide-cel and key takeaways from the ASH 2024 update on minimal residual disease (MRD) negativity rates from CARTITUDE-4 with cilta-cel and its impact on clinical practice.

Sequencing CAR T in More Heavily Pretreated R/R MM as well in patients who deferred initial autologous HSCT

March 31st 2025

Experts discuss their clinical approach to using chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (R/R MM), focusing on how they sequence CAR T with other treatment options like autologous hematopoietic stem cell transplantation (HSCT) and bispecific antibodies.

Optimizing CAR T in R/R MM: Treatment Paradigms and Patient Selection

March 31st 2025

Experts discuss where chimeric antigen receptor (CAR) T-cell therapy currently fits in the treatment paradigm, highlighting the patient factors and disease characteristics that influence its use in clinical decision-making.

Dr Sidana on CAR T-cell Therapy in Patients With R/R Myeloma and Renal Impairment

April 10th 2023

Surbhi Sidana, MD, discusses the unmet needs for patients with relapsed/refractory multiple myeloma who could be candidates for CAR T-cell therapy but have impaired renal function, and how clinical trials for these therapies have excluded this subset of patients.

Dr. Sidana on CAR T-cell Therapy in R/R Multiple Myeloma With Renal Impairment

February 16th 2023

Surbhi Sidana, MD, discusses the feasibility of administering idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma with renal impairment.